“This study clearly demonstrates the potential of combined tissue and fluid proteomics to discover and validate low abundant, tissue-derived biomarkers in peripheral fluids, which in this case resulted in the widest coverage of both tau and phosphorylated tau in human cerebrospinal fluid.
We have been developing several drugs that modulate the phosphorylation of the aggregating protein tau in Alzheimer’s disease by inhibiting the protein casein kinase 1 delta. We have tested them in a model of human tauopathy (aggregating tau diseases) and analyzed brain tissue with SysQuant® to determine the drug’s mechanism of action.
Revenues in the first half are significantly ahead of the equivalent period in 2015 driven principally by strong sales of our TMT® reagents.
We are pleased to announce the appointment of Jeremy Haigh as a director and CEO of the Company on 1st June 2016 as indicated in the press release to shareholders dated 18th May 2016. He is a strong advocate of Precision Medicine and will bring numerous industry contacts and considerable commercial experience to the role.
Against the buoyant background and trajectory of the PS Biomarker Services business it is now appropriate to expand the executive team with a senior figure strongly connected to the pharmaceutical industry and to split the role of Executive Chairman.
The current year started well with a strong order book, increasing amounts of repeat business and a growing pipeline in biomarker services. With the level of SysQuant® /TMTcalibrator™ production doubled the increased capacity is being fully utilised at a time when the volume of customer enquiries is rising on a monthly basis and we are looking to further expand the sales team. Current indications point to a strong performance in 2016.